| INTRODUCTION

Chronic infection with hepatitis C virus (HCV) infection affects
approximately 180 million individuals worldwide. It is a common cause of chronic liver disease and hepatocellular carcinoma in Japan, the United States and many European countries. 1, 2 Chronic infection with HCV is a major cause of progressive liver damage and longterm sequelae such as cirrhosis and hepatocellular carcinoma.
Although most HCV-associated liver damage is immunomediated, 3 some histopathological features, such as liver steatosis, suggest a viral cytopathic effect. 4 Liver steatosis can develop secondary to obesity, diabetes mellitus, alcohol abuse, protein malnutrition, total parenteral nutrition, acute starvation, drug therapy, carbohydrate overload [5] [6] [7] [8] and chronic HCV infection. In patients with chronic HCV infection, the prevalence of steatosis ranges from 40% to 86%. 9 Steatosis occurs more frequently in patients with chronic HCV infection (55%) than in the general adult population (20%-30%) in the Western world. 6 The majority of patients with steatosis (78%) have mild steatosis, with less than 30% of hepatocytes affected.
Interferon-based therapy has been used to treat patients with chronic HCV infection. Many investigators have reported that interferon-based treatment is effective in reducing serum alanine aminotransferase (ALT) levels, eradicating HCV RNA and reducing liver fibrosis in patients with chronic HCV infection. [10] [11] [12] [13] [14] However, interferon-based therapy is associated with several severe treatmentrelated side effects. Direct-acting anti-virals have recently been developed to treat chronic HCV infection. They have resulted in higher sustained virological response (SVR) rates, shorter and simpler regimens, and minimal treatment-related side effects.
The assessment of the severity of liver fibrosis and steatosis is important when staging chronic HCV. Magnetic resonance elastography is a magnetic resonance imaging (MRI)-based method for quantitatively imaging tissue stiffness. Several manufacturers of MRI scanners provide magnetic resonance elastography capabilities as an option through special hardware and software. Magnetic resonance elastography has been reported to be a useful method for diagnosing liver fibrosis in patients with chronic liver disease, even in the early stages. [15] [16] [17] [18] In addition, proton density fat fraction (PDFF) measurement is an MRI-based method for quantitatively assessing liver steatosis. It is an optional addition to MRI scanners from several manufacturers. MRI-determined PDFF correlates with histologically determined steatosis grade in patients with chronic liver disease. [18] [19] [20] Kumar et al 21 reported that viral eradication using interferonbased therapy reduced the steatosis in patients with chronic HCV genotype 3 infection. However, steatosis in chronic HCV patients with genotype 1 or 2 infection who achieve SVR using direct-acting anti-virals has not been sufficiently studied.
In this study, we investigated changes in liver stiffness and steatosis as determined by MRI in patients with chronic HCV genotype 1 or 2 infection who received direct-acting anti-viral therapy and achieved SVR.
| MATERIALS AND METHODS
| Patients
This prospective cohort study was conducted to observe changes in liver stiffness and steatosis as determined by MRI among patients with HCV eradication through interferon-free direct-acting anti-viral therapy (study registration number UMIN000017020 Roche Molecular Systems, Pleasanton, CA, USA; lower limit of detection, 1.2 log 10 IU/mL). HCV genotype was assessed via PCR to amplify the core gene sequences using genotype-specific primers. 25 The presence of known treatment-resistant mutations in the HCV-NS5A region was assessed in all patients with genotype 1b prior to the start of therapy using direct sequencing. 26 At our 2.4 | Assessment of liver stiffness and steatosis
using MRI
All study patients underwent hepatic MRI examination using a 3.0-T whole-body MRI system with a geometry embracing method anterior array coil as the receiver coil (Discovery MR 750W 3.0T; GE Healthcare Japan, Tokyo, Japan) within 2 weeks of the start of direct-acting anti-viral therapy and within 2 weeks of SVR24.
Liver stiffness was evaluated using magnetic resonance elastography, which was performed as follows: continuous longitudinal mechanical waves (60 Hz) were generated using a passive acoustic driver placed against the anterior chest wall. Liver steatosis was evaluated using PDFF, which was measured using a modified Dixon method with advanced processing (IDEAL IQ; GE Healthcare). [28] [29] [30] PDFF methods were performed as follows: In this study, the presence of advanced liver fibrosis (≥F3) was defined as liver stiffness based on magnetic resonance elastography ≥4 kPa, based on a previous report. 31 Regarding steatosis, the presence of fatty liver (steatosis affecting ≥5% of hepatocytes 32 ) was defined as PDFF ≥5.2%, based on a previous report. 33 In addition, the PDFF cut-off values for diagnosing steatosis grades ≥1, ≥2 and ≥3 were 5.2%, 11.3% and 17.1% respectively. 33 Steatosis affecting <5%, 5%-33%, 33%-66% and >66% of hepatocytes was classified as grades 0, 1, 2 and 3 respectively. 34 
| Statistical analysis
Continuous variables are expressed as medians (interquartile range).
The Wilcoxon signed-rank test was used to analyse differences between baseline and SVR24. The Mann-Whitney U test was used for continuous variables and the Chi-squared test with Fisher's exact test was used for categorical variables.
Statistical significance was defined as P < 0.05. All statistical analyses were performed with EZR (Saitama Medical Center, Jichi
Medical University, Saitama, Japan), which is a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria). 35 More precisely, it is a modified version of the R commander designed to add statistical functions frequently used in biostatistics.
3 | RESULTS
| Patient characteristics
The baseline characteristics of all 198 patients are listed in 3.2 | Laboratory data at SVR24 Liver stiffness values evaluated using magnetic resonance elastography at baseline and SVR24 are shown in Figure 1 . Liver stiffness decreased significantly from baseline to SVR24 (P < 0.001).
| Liver steatosis at baseline and SVR24
Liver steatosis values evaluated using MRI-determined PDFF at baseline and SVR24 are shown in Figure 2 . Liver steatosis decreased significantly from baseline to SVR24 (P < 0.001).
3.5 | Liver steatosis at baseline and SVR24 by liver fibrosis severity
Liver steatosis values evaluated using MRI-determined PDFF at baseline and SVR24 in patients without advanced liver fibrosis (liver stiffness based on magnetic resonance elastography at baseline <4 kPa; n = 141) are shown in Figure 3A . Liver steatosis decreased significantly from baseline to SVR24 (P < 0.001).
Liver steatosis values evaluated using MRI-determined PDFF at baseline and SVR24 in patients with advanced liver fibrosis (liver stiffness based on magnetic resonance elastography at baseline ≥4 kPa; n = 57) are shown in Figure 3B . Liver steatosis decreased significantly from baseline to SVR24 (P < 0.001). The baseline characteristics of patients based on status of liver steatosis changes from baseline to SVR24 are listed in Table 2 .
Especially, the patients with decrease in liver steatosis values from baseline to SVR24 showed a significantly higher PDFF values at baseline compared to the patients with increase in liver steatosis values. | 1017 3.9 | Liver stiffness and steatosis at baseline and SVR24 in patients who did not achieve SVR
The baseline characteristics of all 9 patients who received direct-acting anti-viral therapy and did not achieve SVR are listed in Table 3 . Liver biopsy is still considered the gold standard for the evaluation of liver fibrosis and steatosis, even though it is painful and costly. In addition, the spatial variability in steatosis creates the potential for sampling error with liver biopsies, which may result in staging inaccuracies. 38, 39 Moreover, because the invasiveness of liver biopsy precludes repeated examinations, longitudinal evaluation of liver fibrosis and steatosis is difficult. 40 There have been several reports demonstrating the utility of magnetic resonance elastography and MRI-determined PDFF for diagnosing liver fibrosis and steatosis. 18 Tada et al 51 reported that total cholesterol, low-density lipoprotein cholesterol and triglyceride levels are increased by peginterferon and ribavirin combination therapy when patients with HCV genotype 1 infection achieve SVR. Hashimoto et al 52 reported that the increase in total cholesterol levels during treatment was much greater in the ledipasvir/sofosbuvir group who achieved SVR than in the daclatasvir and asunaprevir group who achieved SVR. They also found that a rapid increase in serum low-density lipoprotein cholesterol levels during interferon-free treatment was associated with regimen type and decreased HCV core protein levels. Therefore, HCV eradication is closely related to lipid metabolism in patients treated with anti-viral therapy. In this study, we also found that total cholesterol, high- density lipoprotein cholesterol and low-density lipoprotein cholesterol levels increased significantly from baseline to SVR24. Although triglyceride levels did not change significantly between baseline and SVR24, in patients with high triglyceride levels (≥150 mg/dL) triglyceride levels decreased significantly from baseline to SVR24.
In patients with chronic HCV infection, insulin resistance and type 2 diabetes are major disease modifiers. 53 They are associated with poor outcomes such as accelerated liver fibrosis progression, reduced SVR rates, development of hepatocellular carcinoma and cardiovascular events such as acute coronary syndrome. 54 Recently, we reported that HCV eradication with interferon-based therapy reduced not only liver-related mortality but also nonliver-related mortality in patients with chronic HCV infection. 55 In this study, we found that insulin resistance as assessed by HOMA-IR decreased from baseline to SVR24 in patients with chronic HCV infection who received direct-acting anti-viral therapy. Metabolic steatosis is largely due to insulin resistance. Therefore, the reduction in liver steatosis based on PDFF was associated not only with direct HCV eradication but also lower insulin resistance in patients with chronic HCV infection who received direct-acting anti-viral therapy and achieved SVR.
In the future, a decrease in insulin resistance associated with metabolic steatosis in patients with chronic HCV infection who received F I G U R E 6 Liver stiffness and PDFF at baseline and SVR24 in patients who did not achieve SVR. (A) Liver stiffness. The liver stiffness at baseline and SVR24 were 5.80 (4.00-7.80) kPa and 6.10 (3.6-7.60) kPa respectively. There were no significant changes between baseline and SVR24 (P = 0.820). (B) PDFF. The PDFF at baseline and SVR24 were 2.6 (1.6-3.8)% and 2.5 (1.2-2.6)% respectively. There were no significant changes between baseline and SVR24 (P = 0.080). SVR was confirmed by the absence of serum HCV RNA at 24 wk after the end of treatment (SVR24). The box represents the interquartile range. The line through the box indicates the median. The bottom error bar indicates the 25th percentile À 1.5 9 interquartile range and the top error bar indicates the 75th percentile + 1.5 9 interquartile range. PDFF, proton density fat fraction; SVR, sustained virological response direct-acting anti-viral therapy and achieved SVR is expected to suppress the progression to nonliver-related diseases such as cardiovascular disease.
The main limitations of this study include the relatively small number of patients with chronic HCV infection who achieved SVR.
Future studies with more patients are warranted. Another limitation of this study was the short follow-up period. Tachi 
